Tirzepatide is the better fit when risk is stacked: significant obesity plus diabetes, MASLD, sleep apnea, or multiple cardiovascular risk factors, where the priority is maximum multimarker change in the shortest safe window. Semaglutide is the better fit when risk is moderate or the patient (or insurer) wants the longest, clearest outcome data: obesity with earlierstage cardiometabolic disease, where strong improvements and proven event reduction are enough without deploying dualagonist intensity. How Do Tirzepatide and Semaglutide Support Liver and Sleep Health
[DOI] [PMC free article] [PubMed] [Google Scholar] 130.Brindisi M.C., Brondel L., Meillon S., Barthet S., Grall S., Fenech C., Linard F., Schlich P., Astruc K., Mouillot T., et al
Fadini GP, et al
Trusted Supplier Purchasing directly from NEXAPH helps customers avoid counterfeit or low-quality products commonly found through unauthorized vendors